Table 4.

Clinical adverse effects

	Overall	H101	Control	P value
Fever				0.023
> 38.5 °C	55.4 %	64.4 %	46.6 %
≤ 38.5 °C	44.6 %	35.6 %	53.4 %
Pain				0.875
Yes	65.1 %	64.4 %	65.9 %
No	34.9 %	35.6 %	34.1 %
Ascites				0.864
Yes	25.7 %	26.4 %	25 %
No	74.3 %	73.6 %	75 %
Acute renal failure
Yes	5.1 %	5.7 %	4.5 %	0.896
No	94.9 %	94.3 %	95.5 %
Encephalopathy
Yes	0	0	0
No	100 %	100 %	100 %
White Blood Cell
Before TACE	5.7	6.0	5.5	0.369
After TACE	7.64	7.0	8.84	0.991
Elevation	1.61	0.5	2.97	0.001
PLT
Before	167.0	179.2	154.5	0.186
After	113.0	122.8	106.1	0.258
Elevation	49.0	52.7	48.4	0.480
ALT
Before	41.5	43.2	41.4	0.371
After	167.1	153.0	200.9	0.405
Elevation	103.1	88.1	118.4	0.480
AST
Before	50.9	57.1	46.4	0.249
After	221.3	225.4	213.5	0.993
Elevation	154.2	141.2	162.0	0.863
TBIL
Before	16.3	16.1	16.8	0.657
After	30.4	28.3	31.8	0.162
Elevation	12.9	12.4	13.25	0.413
ALB
Before	40.0	38.2	41.2	0.161
After	35.4	34.1	37.0	0.314
Elevation	4.1	3.6	4.4	0.226

PLT platelet count, ALB albumin, ALT alanine aminotransferase, AST aspartate aminotransferase, PLT platelet, TACE transhepatic arterial chemoembolization, TBIL total bilirubin